title: Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies.
abstract: Monoclonal antibodies are important therapeutic tools, but their usefulness is limited in patients who experience acute infusion reactions, most of which are consistent with type I hypersensitivity reactions including anaphylaxis. Patients who experience acute infusion reactions face the prospect of stopping treatment or switching to an alternative, and potentially more toxic or inferior treatment. Another option that overcomes the treatment hurdle of these reactions is rapid desensitization, a procedure in which the offending agent is re-administered in a step-wise, highly controlled fashion. While the risk of reactions is not completely eliminated, desensitization has proven to be a highly effective re-administration strategy for most patients who otherwise would not be able to tolerate their monoclonal antibody therapy owing to drug-induced anaphylaxis. This article reviews the current literature on desensitization and other readministration protocols to monoclonal antibodies with an emphasis on four agents: rituximab, infliximab, cetuximab and trastuzumab.
authors.affiliation: Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
authors.forename: David I
authors.initials: DI
authors.lastname: Hong
authors.forename: Lora
authors.initials: L
authors.lastname: Bankova
authors.forename: Katherine N
authors.initials: KN
authors.lastname: Cahill
authors.forename: Timothy
authors.initials: T
authors.lastname: Kyin
authors.forename: Mariana C
authors.initials: MC
authors.lastname: Castells
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced / Q000517:prevention & control*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003888:Desensitization, Immunologic / Q000379:methods*; D004342:Drug Hypersensitivity / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal